Rises as VERVE-102 Trial Shows LDL-C Drop

TLDR

• Eli Lilly stock rises as VERVE-102 shows durable LDL-C reduction

• VERVE-102 trial data lifts LLY after strong PCSK9 and LDL-C drops

• Lilly shares gain as one-time gene editing therapy posts early results

• VERVE-102 shows sustained LDL-C cuts in early cardiovascular study

• Eli Lilly advances VERVE-102 after positive Phase 1b Heart-2 data

Eli Lilly (LLY) Stock Rises as VERVE-102 Trial Shows LDL-C Drop after positive early heart data. LLY traded at $1,065.00, up $23.35, or 2.24%, after holding firm gains. The move followed new Phase 1b results showing durable LDL-C reductions from VERVE-102.

Eli Lilly and Company, LLY

VERVE-102 Shows Strong LDL-C Reduction

Eli Lilly gained after the company announced results for VERVE-102. The medicine targets the PCSK9 gene in the liver through in vivo base editing. It aims to lower LDL-C after a single intravenous infusion.

The Heart-2 trial enrolled adults with heterozygous familial hypercholesterolemia or premature coronary artery disease. The interim analysis covered 35 participants across several dose levels. Lilly presented the results at the European Atherosclerosis Society Congress.

VERVE-102 reduced circulating PCSK9 protein in a dose-dependent pattern. Mean PCSK9 reductions ranged from 51% at 0.3 mg/kg to 88% at 1.0 mg/kg. Corresponding LDL-C reductions reached 62% at the highest evaluated dose.

Safety Data Supports Further Development

Eli Lilly also drew attention because the trial showed a clean early safety profile. The company reported no treatment-related serious adverse events. It also reported no dose-limiting toxicities across tested doses.

Reported treatment-related events included low-grade infusion reactions and fatigue. However, all participants received the full planned dose. In addition, no participant withdrew from the Heart-2 study.

The reductions also lasted over time in follow-up data. Lilly reported durability for up to 18 months after treatment. Therefore, the results support further testing in a larger clinical setting.

Lilly Plans Phase 2 Study This Year

Eli Lilly and Company stock remains tied to broader interest in cardiovascular innovation. VERVE-102 targets patients who face high lifetime cardiovascular risk. The FDA has granted Fast Track designation for reducing LDL-C in eligible patients.

HeFH affects about one in 200 to 250 people. The condition causes lifelong elevated LDL-C and raises the risk of early cardiovascular disease. Coronary artery disease affects more than 300 million people worldwide.

Eli Lilly and Company stock gained as the company confirmed its next development step. Lilly plans to start a Phase 2 clinical study by year-end. Consequently, VERVE-102 now moves from early proof toward broader clinical testing.